<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8" />
    <title>Optic Neuritis in Multiple Sclerosis - 50 Slides</title>

    <!-- Reveal.js Core CSS -->
    <link
      rel="stylesheet"
      href="https://cdn.jsdelivr.net/npm/reveal.js@4.5.0/dist/reveal.css"
    />

    <!-- Reveal.js Theme (White) -->
    <link
      rel="stylesheet"
      href="https://cdn.jsdelivr.net/npm/reveal.js@4.5.0/dist/theme/white.css"
      id="theme"
    />

    <!-- Google Font: Open Sans -->
    <link
      rel="stylesheet"
      href="https://fonts.googleapis.com/css2?family=Open+Sans&display=swap"
    />

    <style>
      /* Global font and color settings */
      body,
      .reveal {
        font-family: "Open Sans", sans-serif;
        color: #333;
      }

      /* Fixed presentation header at top */
      .presentation-header {
        position: fixed;
        top: 0;
        left: 0;
        width: 100%;
        background: linear-gradient(90deg, #4a90e2, #357abd);
        color: #fff;
        text-align: center;
        padding: 0.8em 0;
        z-index: 1000;
        box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
      }
      .presentation-header h1 {
        margin: 0;
        font-size: 1.5em;
      }

      /* Ensure the reveal container does not get hidden under the fixed header */
      .reveal {
        margin-top: 50px;
      }

      /* Slide styling for a clean, card-like appearance */
      .reveal .slides section {
        padding: 1.5em;
        border-radius: 8px;
        box-shadow: 0 2px 8px rgba(0, 0, 0, 0.1);
        background-color: #ffffff;
      }

      /* Small section header above main slide titles */
      /* .slide-header {
        font-size: 0.9em;
        color: #777;
        text-transform: uppercase;
        letter-spacing: 1px;
        margin-bottom: 0.3em;
      } */

      /* Main slide title styling */
      /* .reveal h2 {
        font-size: 1.8em;
        margin-top: 0.2em;
        margin-bottom: 0.5em;
        color: #2c3e50;
        border-bottom: 2px solid #4a90e2;
        padding-bottom: 0.3em;
      } */

      /* List styling */
      /* .reveal ul,
      .reveal ol {
        font-size: 1em;
        line-height: 1.6em;
        margin-left: 1.2em;
      } */

      /* Title slide styling */
      /* section.title-slide {
        text-align: center;
        background-color: #f7f7f7;
        color: #2c3e50;
        padding: 2em;
      } */

      /* References slide styling */
      /* section.references-slide {
        background-color: #fdfefe;
        padding: 2em;
      } */
    </style>
  </head>
  <body>
    <!-- Fixed header with presentation title -->
    <header class="presentation-header">
      <h1>Optic Neuritis in Multiple Sclerosis</h1>
    </header>

    <div class="reveal">
      <div class="slides">
        <!-- Slide 1 (Title) -->
        <section class="title-slide">
          <div class="slide-header">Title</div>
          <h2>Optic Neuritis in Multiple Sclerosis</h2>
          <h3>
            A Comprehensive Review (History, Exam, Diagnosis &amp; Management)
          </h3>
          <p>Presented by: Sanaa</p>
          <p>MediVision Eye Care Centre</p>
        </section>

        <!-- Slide 2: Outline -->
        <section>
          <h2>Outline</h2>
          <ul>
            <li>Introduction</li>
            <li>Epidemiology &amp; Risk Factors</li>
            <li>Pathophysiology</li>
            <li>Types of Optic Neuritis</li>
            <li>Relationship Between ON &amp; MS</li>
            <li>Clinical Features</li>
            <li>History Taking</li>
            <li>Clinical Examination</li>
          </ul>
          <ul>
            <li>Investigations</li>
            <li>Differential Diagnosis</li>
            <li>Management</li>
            <li>Prognosis &amp; Follow-Up</li>
            <li>Special Considerations &amp; Future Directions</li>
            <li>Conclusion</li>
            <li>References</li>
          </ul>
        </section>

        <!-- Slide 3: Definition of ON -->
        <section>
          <div class="slide-header">Section 2</div>
          <h2>Definition of Optic Neuritis</h2>
          <ul>
            <li>
              <strong>Optic Neuritis (ON):</strong> Inflammatory demyelination
              of the optic nerve
            </li>
            <li>
              <strong>Presentation:</strong> Subacute onset of unilateral vision
              loss, eye pain
            </li>
            <li>
              <strong>Significance:</strong> Often the first manifestation of MS
            </li>
          </ul>
        </section>

        <!-- Slide 4: Importance of Studying ON in MS -->
        <section>
          <div class="slide-header">Section 2</div>
          <h2>Importance of Studying ON in MS</h2>
          <ul>
            <li>
              ON is often the <strong>first demyelinating event</strong> in MS
            </li>
            <li>~15–20% of MS patients initially present with ON</li>
            <li>
              Provides insight into <strong>autoimmune demyelination</strong> in
              the CNS.
            </li>
            <li>Early detection can prompt disease-modifying therapies</li>
          </ul>
        </section>

        <!-- Slide 5: Epidemiology -->
        <section>
          <div class="slide-header">Section 3</div>
          <h2>Epidemiology</h2>
          <ul>
            <li><strong>Age:</strong> Typically 20–40 years</li>
            <li><strong>Gender:</strong> Female predominance (~3:1)</li>
            <li>
              <strong>Geographic Variation:</strong> Higher incidence farther
              from the equator
            </li>
            <li>
              <strong>Association:</strong> 50% of isolated ON develop MS within
              15 years
            </li>
          </ul>
        </section>

        <!-- Slide 6: Risk Factors -->
        <section>
          <div class="slide-header">Section 3</div>
          <h2>Risk Factors</h2>
          <ul>
            <li>
              <strong>Genetic Predisposition:</strong> Certain HLA genotypes
            </li>
            <li>
              <strong>Environmental Factors:</strong>
              <ul>
                <li>Low Vitamin D</li>
                <li>Smoking</li>
                <li>Viral triggers (EBV association)</li>
              </ul>
            </li>
            <li><strong>Autoimmune Disorders:</strong> May predispose to ON</li>
          </ul>
        </section>

        <!-- Slide 7: Basic Immunopathology -->
        <section>
          <div class="slide-header">Section 4</div>
          <h2>Basic Immunopathology</h2>
          <ul>
            <li>
              <strong>Autoimmune Attack:</strong> T-cells, B-cells, and
              antibodies target myelin
            </li>
            <li>
              <strong>Key Cells:</strong> CD4+, CD8+ T cells, B cells,
              macrophages
            </li>
            <li>
              <strong>Inflammatory Cascade:</strong> Cytokines (IL-2, IFN-γ)
              promote demyelination, axonal injury
            </li>
          </ul>
        </section>

        <!-- Slide 8: Demyelination in the Optic Nerve -->
        <section>
          <div class="slide-header">Section 4</div>
          <h2>Demyelination in the Optic Nerve</h2>
          <ul>
            <li><strong>Myelin Loss:</strong> Slows nerve conduction</li>
            <li>
              <strong>Axonal Injury:</strong> Potentially permanent if severe
            </li>
            <li>
              <strong>Remyelination:</strong> Explains partial or full visual
              recovery.
            </li>
          </ul>
        </section>

        <!-- Slide 9: Role of MS Plaques -->
        <section>
          <div class="slide-header">Section 4</div>
          <h2>Role of MS Plaques</h2>
          <ul>
            <li><strong>MS Plaques:</strong> Focal CNS demyelination</li>
            <li>
              <strong>Locations:</strong> Periventricular, juxtacortical,
              infratentorial, spinal cord
            </li>
            <li>
              <strong>MRI:</strong> T2/FLAIR lesions; active lesions enhance
              with gadolinium
            </li>
            <li>
              <strong>Optic Nerve Lesions:</strong> Enhancement indicates acute
              ON inflammation.
            </li>
          </ul>
        </section>

        <!-- Slide 10: Typical vs. Atypical ON -->
        <section>
          <div class="slide-header">Section 5</div>
          <h2>Typical vs. Atypical ON</h2>
          <ul>
            <li>
              <strong>Typical (Demyelinating) ON:</strong>
              <ul>
                <li>Often associated with MS</li>
                <li>Usually unilateral, painful, better recovery</li>
                <li>MRI often shows MS-like lesions</li>
              </ul>
            </li>
            <li>
              <strong>Atypical ON:</strong>
              <ul>
                <li>Causes: NMO, MOG, infections, sarcoidosis</li>
                <li>Often bilateral or severe; may have worse prognosis</li>
              </ul>
            </li>
          </ul>
        </section>

        <!-- Slide 11: Clinical Clues to Atypical ON -->
        <section>
          <div class="slide-header">Section 5</div>
          <h2>Clinical Clues to Atypical ON</h2>
          <ul>
            <li>Poor steroid response</li>
            <li>Recurrent bilateral involvement</li>
            <li>Severe vision loss at onset</li>
            <li>Systemic symptoms (rash, arthralgias)</li>
            <li>Marked disc swelling on imaging</li>
          </ul>
        </section>

        <!-- Slide 12: ON as an Early Indicator of MS -->
        <section>
          <div class="slide-header">Section 5</div>
          <h2>ON as an Early Indicator of MS</h2>
          <ul>
            <li>15–20% of MS patients present with ON initially</li>
            <li>~50% develop MS within 15 years after first ON</li>
            <li>MRI brain lesions greatly increase MS conversion risk</li>
          </ul>
        </section>

        <!-- Slide 13: MS Diagnostic Criteria (Brief) -->
        <section>
          <div class="slide-header">Section 6</div>
          <h2>MS Diagnostic Criteria (Brief)</h2>
          <ul>
            <li>
              <strong>McDonald Criteria:</strong> Dissemination in time &amp;
              space.
            </li>
            <li>
              <strong>Clinical Attacks + MRI Evidence:</strong>
              <ul>
                <li>≥2 CNS regions (space)</li>
                <li>Lesions at different times (time)</li>
              </ul>
            </li>
            <li>Optic Neuritis can fulfill part of the clinical criteria.</li>
          </ul>
        </section>

        <!-- Slide 14: Vision Loss -->
        <section>
          <div class="slide-header">Section 6</div>
          <h2>Vision Loss</h2>
          <ul>
            <li>
              <strong>Nature:</strong> Sudden or subacute onset over days to ~1
              week
            </li>
            <li>
              <strong>Severity:</strong> Mild blurring to complete vision loss
            </li>
            <li>
              <strong>Laterality:</strong> Typically unilateral in demyelinating
              ON
            </li>
            <li>
              <strong>Progression:</strong> Often worsens for ~1 week, then
              stabilizes/improves
            </li>
          </ul>
        </section>

        <!-- Slide 15: Pain with Eye Movement -->
        <section>
          <div class="slide-header">Section 6</div>
          <h2>Pain with Eye Movement</h2>
          <ul>
            <li>
              ~90% of patients report orbital pain, worsened by eye movement
            </li>
            <li>Due to inflammation of the optic nerve sheath</li>
          </ul>
        </section>

        <!-- Slide 16: Color Vision Defects -->
        <section>
          <div class="slide-header">Section 6</div>
          <h2>Color Vision Defects</h2>
          <ul>
            <li>Red desaturation is a hallmark of ON</li>
            <li>Ishihara plates may show color discrimination deficits</li>
            <li>
              Residual color vision changes can persist even after acuity
              improves
            </li>
          </ul>
        </section>

        <!-- Slide 17: Visual Field Defects -->
        <section>
          <div class="slide-header">Section 6</div>
          <h2>Visual Field Defects</h2>
          <ul>
            <li>Most common: Central or cecocentral scotoma</li>
            <li>Diffuse field loss or altitudinal defect is less frequent</li>
            <li>Confrontation test (screen), automated perimetry (detailed)</li>
          </ul>
        </section>

        <!-- Slide 18: Uhthoff’s Phenomenon -->
        <section>
          <div class="slide-header">Section 6</div>
          <h2>Uhthoff’s Phenomenon</h2>
          <ul>
            <li>Worsening of neurological symptoms with heat/exercise</li>
            <li>
              Elevated body temperature further impairs conduction in
              demyelinated axons
            </li>
            <li>Can transiently reduce visual acuity</li>
          </ul>
        </section>

        <!-- Slide 19: Relative Afferent Pupillary Defect (RAPD) -->
        <section>
          <div class="slide-header">Section 6</div>
          <h2>Relative Afferent Pupillary Defect (RAPD)</h2>
          <ul>
            <li>
              Use the swinging flashlight test to detect unilateral/asymmetric
              dysfunction
            </li>
            <li>
              More pronounced RAPD generally indicates more severe ON
              involvement
            </li>
          </ul>
        </section>

        <!-- Slide 20: History Taking (Part 1) -->
        <section>
          <div class="slide-header">Section 7</div>
          <h2>Key Points in History (Part 1)</h2>
          <ul>
            <li>Chief complaint: Exact nature &amp; onset of vision loss</li>
            <li>Pain: Especially with eye movement</li>
            <li>Timeline: Duration, progression</li>
            <li>Possible triggers: Recent infection, vaccination, or stress</li>
          </ul>
        </section>

        <!-- Slide 21: History Taking (Part 2) -->
        <section>
          <div class="slide-header">Section 7</div>
          <h2>Key Points in History (Part 2)</h2>
          <ul>
            <li>
              <strong>Systemic Review:</strong>
              <ul>
                <li>Neurological: numbness, weakness, ataxia</li>
                <li>Urinary changes, diplopia</li>
              </ul>
            </li>
            <li>
              <strong>Past Medical History:</strong>
              <ul>
                <li>Previous ON episodes</li>
                <li>Known autoimmune/neuro disorders</li>
              </ul>
            </li>
            <li>
              <strong>Family History:</strong> MS or other autoimmune diseases
            </li>
          </ul>
        </section>

        <!-- Slide 22: Additional History Details -->
        <section>
          <div class="slide-header">Section 7</div>
          <h2>Additional History Details</h2>
          <ul>
            <li>Medication Use: steroids, immunomodulators, etc.</li>
            <li>Social History: smoking, alcohol, occupation</li>
            <li>Travel History: risk for infections</li>
            <li>
              Red Flags: Systemic signs like fever, weight loss, or night sweats
            </li>
          </ul>
        </section>

        <!-- Slide 23: Visual Acuity Testing -->
        <section>
          <div class="slide-header">Section 8</div>
          <h2>Visual Acuity Testing</h2>
          <ul>
            <li>Measure best-corrected VA (Snellen, ETDRS)</li>
            <li>Compare findings with the contralateral eye</li>
            <li>Check for pinhole improvement</li>
          </ul>
        </section>

        <!-- Slide 24: Pupillary Examination -->
        <section>
          <div class="slide-header">Section 8</div>
          <h2>Pupillary Examination</h2>
          <ul>
            <li>Size, shape, symmetry</li>
            <li>Direct &amp; consensual light reflex</li>
            <li>Swinging flashlight test (RAPD)</li>
            <li>Near response (accommodation, convergence)</li>
          </ul>
        </section>

        <!-- Slide 25: Color Vision Testing -->
        <section>
          <div class="slide-header">Section 8</div>
          <h2>Color Vision Testing</h2>
          <ul>
            <li>Ishihara plates to screen for color defects</li>
            <li>Red desaturation test for subtle differences</li>
            <li>Document severity/persistence of color deficits</li>
          </ul>
        </section>

        <!-- Slide 26: Visual Field Evaluation -->
        <section>
          <div class="slide-header">Section 8</div>
          <h2>Visual Field Evaluation</h2>
          <ul>
            <li>Confrontation testing (screening)</li>
            <li>Automated perimetry (e.g., Humphrey) for detailed mapping</li>
            <li>Identify scotomas or generalized field loss</li>
          </ul>
        </section>

        <!-- Slide 27: Fundoscopic Examination -->
        <section>
          <div class="slide-header">Section 9</div>
          <h2>Fundoscopic Examination</h2>
          <ul>
            <li>Acute ON often normal disc (retrobulbar neuritis)</li>
            <li>Possible disc swelling (papillitis)</li>
            <li>Chronic: optic disc pallor indicates atrophy</li>
          </ul>
        </section>

        <!-- Slide 28: Neurological Examination -->
        <section>
          <div class="slide-header">Section 9</div>
          <h2>Neurological Examination</h2>
          <ul>
            <li>Cranial Nerves: check EOMs (III, IV, VI), CN V, etc.</li>
            <li>Motor: weakness, spasticity</li>
            <li>Sensory: pinprick, proprioception</li>
            <li>Coordination: ataxia tests; Gait: spastic or unsteady gait</li>
          </ul>
        </section>

        <!-- Slide 29: MRI of the Brain & Orbits (Part 1) -->
        <section>
          <div class="slide-header">Section 10</div>
          <h2>MRI of the Brain &amp; Orbits (1)</h2>
          <ul>
            <li>
              <strong>Purpose:</strong> Identify CNS demyelinating lesions
            </li>
            <li>
              <strong>Optic Nerve Enhancement:</strong> T1 + gadolinium → active
              inflammation
            </li>
            <li>
              <strong>T2/FLAIR:</strong> Hyperintensities showing older/new
              plaques
            </li>
          </ul>
        </section>

        <!-- Slide 30: MRI of the Brain & Orbits (Part 2) -->
        <section>
          <div class="slide-header">Section 10</div>
          <h2>MRI of the Brain &amp; Orbits (2)</h2>
          <ul>
            <li>
              <strong>High MS Risk:</strong> Multiple lesions, especially
              periventricular
            </li>
            <li>
              <strong>Optic Nerve Findings:</strong> Enhancement, swelling in
              acute ON
            </li>
          </ul>
        </section>

        <!-- Slide 31: Visual Evoked Potentials (VEP) -->
        <section>
          <div class="slide-header">Section 10</div>
          <h2>Visual Evoked Potentials (VEP)</h2>
          <ul>
            <li>Measures conduction speed from retina to occipital cortex</li>
            <li>Prolonged P100 latency indicates demyelination</li>
            <li>Useful for subclinical lesions, supports MS diagnosis</li>
          </ul>
        </section>

        <!-- Slide 32: Optical Coherence Tomography (OCT) -->
        <section>
          <div class="slide-header">Section 10</div>
          <h2>Optical Coherence Tomography (OCT)</h2>
          <ul>
            <li>
              Cross-sectional imaging of the retinal nerve fiber layer (RNFL)
            </li>
            <li>Thinning of RNFL indicates axonal loss after ON</li>
            <li>Helps monitor disease progression or treatment response</li>
          </ul>
        </section>

        <!-- Slide 33: Additional Laboratory Tests -->
        <section>
          <div class="slide-header">Section 11</div>
          <h2>Additional Laboratory Tests</h2>
          <ul>
            <li><strong>Serologic:</strong> NMO-IgG (AQP4), MOG-IgG</li>
            <li>
              <strong>Basic Labs:</strong> CBC, ESR, CRP, ANA (rule out systemic
              causes)
            </li>
            <li><strong>CSF:</strong> Oligoclonal bands supportive of MS</li>
          </ul>
        </section>

        <!-- Slide 34: Major Differentials -->
        <section>
          <div class="slide-header">Section 12</div>
          <h2>Major Differentials</h2>
          <ul>
            <li>Neuromyelitis Optica (NMO)</li>
            <li>MOG Antibody Disease</li>
            <li>Ischemic Optic Neuropathy</li>
            <li>Leber’s Hereditary Optic Neuropathy</li>
            <li>Infectious Optic Neuritis (e.g., syphilis, Lyme)</li>
            <li>Sarcoid/Autoimmune ON</li>
          </ul>
        </section>

        <!-- Slide 35: Clues to Differentials -->
        <section>
          <div class="slide-header">Section 12</div>
          <h2>Clues to Differentials</h2>
          <ul>
            <li>
              <strong>NMO:</strong> Severe, bilateral, spinal cord lesions
              (longitudinally extensive)
            </li>
            <li><strong>MOG-ON:</strong> Disc swelling, often good recovery</li>
            <li>
              <strong>Ischemic ON:</strong> Painless, altitudinal defect, older
              patients
            </li>
            <li>
              <strong>Leber’s:</strong> Gradual bilateral central loss, maternal
              inheritance
            </li>
            <li>
              <strong>Infectious:</strong> Systemic signs, positive serologies
            </li>
          </ul>
        </section>

        <!-- Slide 36: General Approach to Management -->
        <section>
          <div class="slide-header">Section 13</div>
          <h2>General Approach to Management</h2>
          <ul>
            <li>Confirm diagnosis: Clinical + MRI (+/- VEP)</li>
            <li>Assess MS risk: Brain MRI for demyelinating lesions</li>
            <li>Exclude atypical causes: NMO-IgG, MOG-IgG if suspicion</li>
          </ul>
        </section>

        <!-- Slide 37: High-Dose Corticosteroids -->
        <section>
          <div class="slide-header">Section 13</div>
          <h2>High-Dose Corticosteroids</h2>
          <ul>
            <li>
              First-line for acute ON: IV methylprednisolone 1 g/day x 3–5 days
            </li>
            <li>Oral steroids may follow IV or be used if mild</li>
            <li>Speeds recovery but doesn’t always alter long-term final VA</li>
          </ul>
        </section>

        <!-- Slide 38: Disease-Modifying Therapies (DMTs) -->
        <section>
          <div class="slide-header">Section 13</div>
          <h2>Disease-Modifying Therapies (DMTs)</h2>
          <ul>
            <li>Indicated if MS or high MS risk is confirmed</li>
            <li>
              Examples:
              <ul>
                <li>Interferon β-1a/b</li>
                <li>Glatiramer acetate</li>
                <li>Dimethyl fumarate</li>
                <li>Natalizumab, Ocrelizumab, etc.</li>
              </ul>
            </li>
            <li>Reduce relapse frequency &amp; slow progression</li>
          </ul>
        </section>

        <!-- Slide 39: Other Immunomodulatory Therapies -->
        <section>
          <div class="slide-header">Section 13</div>
          <h2>Other Immunomodulatory Therapies</h2>
          <ul>
            <li>
              <strong>NMO:</strong> Steroids + possible plasmapheresis;
              long-term rituximab or similar
            </li>
            <li>
              <strong>MOG-ON:</strong> Steroids, IVIG, or other
              immunosuppressants depending on severity
            </li>
            <li>Goal: Address underlying autoimmune process</li>
          </ul>
        </section>

        <!-- Slide 40: Plasma Exchange (Plasmapheresis) -->
        <section>
          <div class="slide-header">Section 13</div>
          <h2>Plasma Exchange (Plasmapheresis)</h2>
          <ul>
            <li>Indicated for steroid-refractory acute ON</li>
            <li>Removes circulating autoantibodies and immune complexes</li>
            <li>May improve vision in refractory demyelinating ON</li>
          </ul>
        </section>

        <!-- Slide 41: Symptomatic Management -->
        <section>
          <div class="slide-header">Section 14</div>
          <h2>Symptomatic Management</h2>
          <ul>
            <li>Pain control: NSAIDs, acetaminophen</li>
            <li>Vision aids: large print, contrast enhancements</li>
            <li>Cooling strategies: to mitigate Uhthoff’s phenomenon</li>
          </ul>
        </section>

        <!-- Slide 42: Natural Course of ON -->
        <section>
          <div class="slide-header">Section 14</div>
          <h2>Natural Course of ON</h2>
          <ul>
            <li>
              Partial recovery often starts in 2–4 weeks, continues for months
            </li>
            <li>Generally good final visual outcome in typical ON</li>
            <li>Mild residual color or contrast deficits can persist</li>
          </ul>
        </section>

        <!-- Slide 43: Risk of Progression to MS -->
        <section>
          <div class="slide-header">Section 14</div>
          <h2>Risk of Progression to MS</h2>
          <ul>
            <li>High lesion load on MRI = higher MS risk</li>
            <li>Monitor with repeat exams &amp; MRIs if new symptoms arise</li>
            <li>Early DMT may delay or reduce MS progression</li>
          </ul>
        </section>

        <!-- Slide 44: Optic Neuritis Treatment Trial (ONTT) -->
        <section>
          <div class="slide-header">Section 14</div>
          <h2>Optic Neuritis Treatment Trial (ONTT)</h2>
          <ul>
            <li>Landmark trial: steroids vs. placebo in acute ON</li>
            <li>
              IV steroids hastened recovery but no major long-term VA difference
            </li>
            <li>Oral steroids alone had higher short-term recurrence</li>
            <li>MRI lesions predicted higher MS risk</li>
          </ul>
        </section>

        <!-- Slide 45: Pediatric Optic Neuritis -->
        <section>
          <div class="slide-header">Section 15</div>
          <h2>Pediatric Optic Neuritis</h2>
          <ul>
            <li>Often bilateral in children</li>
            <li>May follow viral infection or vaccination</li>
            <li>High-dose steroids; evaluate for demyelinating disease</li>
          </ul>
        </section>

        <!-- Slide 46: Pregnancy and ON/MS -->
        <section>
          <div class="slide-header">Section 15</div>
          <h2>Pregnancy and ON/MS</h2>
          <ul>
            <li>
              MS relapses may decrease during pregnancy, rebound postpartum
            </li>
            <li>
              Some DMTs contraindicated in pregnancy; adjust therapy accordingly
            </li>
            <li>Short-term IV steroids are generally safe if needed</li>
          </ul>
        </section>

        <!-- Slide 47: Emerging Therapies -->
        <section>
          <div class="slide-header">Section 15</div>
          <h2>Emerging Therapies</h2>
          <ul>
            <li>
              Neuroprotective agents: Aiming to protect axons in acute
              inflammation
            </li>
            <li>Remyelinating therapies: Enhance repair of myelin sheath</li>
            <li>
              Biologics: New monoclonal antibodies targeting specific immune
              pathways
            </li>
          </ul>
        </section>

        <!-- Slide 48: Patient Education & Support -->
        <section>
          <div class="slide-header">Section 16</div>
          <h2>Patient Education &amp; Support</h2>
          <ul>
            <li>Explain ON &amp; MS link, possible disease course</li>
            <li>Lifestyle: Avoid smoking, ensure Vitamin D, manage stress</li>
            <li>Resources: MS societies, vision rehab programs, counseling</li>
          </ul>
        </section>

        <!-- Slide 49: Key Takeaways -->
        <section>
          <div class="slide-header">Section 16</div>
          <h2>Key Takeaways</h2>
          <ul>
            <li>
              ON: acute unilateral vision loss, eye pain, color desaturation
            </li>
            <li>Often first sign of MS; ~50% risk of MS over 15 years</li>
            <li>Diagnosis: history, exam (RAPD, color vision, VF), MRI, VEP</li>
            <li>
              Management: High-dose IV steroids, DMT if MS risk; generally good
              recovery
            </li>
          </ul>
        </section>

        <!-- Slide 50: References -->
        <section class="references-slide">
          <div class="slide-header">References</div>
          <h2>References</h2>
          <ul>
            <li>
              WebMD:
              <a
                href="https://www.webmd.com/multiple-sclerosis/optic-neuritis-ms-vision"
                target="_blank"
                >Optic Neuritis in MS</a
              >
            </li>
            <li>
              PubMed:
              <a
                href="https://pubmed.ncbi.nlm.nih.gov/12789593/"
                target="_blank"
                >Optic Neuritis &amp; MS (PMID 12789593)</a
              >
            </li>
            <li>Optic Neuritis Treatment Trial (ONTT) Publications</li>
            <li>National Multiple Sclerosis Society</li>
            <li>UpToDate: Optic Neuritis – Diagnosis &amp; Management</li>
          </ul>
          <p><strong>Thank You!</strong></p>
        </section>
      </div>
    </div>

    <!-- Reveal.js Scripts -->
    <script src="https://cdn.jsdelivr.net/npm/reveal.js@4.5.0/dist/reveal.js"></script>
    <script>
      Reveal.initialize({
        hash: true, // URL hash navigation
        slideNumber: true, // Display slide numbers
        controls: true, // Navigation arrows
        progress: true, // Progress bar
        center: true, // Center slides vertically
        transition: "slide", // Slide transition style
        width: "100%",
        height: "100%",
      });
    </script>
  </body>
</html>
